Fennec Pharmaceuticals, Inc. (FENC)
10.71
+0.08
(+0.75%)
USD |
NASDAQ |
Oct 09, 16:00
10.68
-0.02
(-0.23%)
After-Hours: 20:00
Fennec Pharmaceuticals Enterprise Value : 333.97M for Oct. 9, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 09, 2026 | 333.97M |
| October 08, 2026 | 331.16M |
| October 07, 2026 | 321.70M |
| October 06, 2026 | 321.35M |
| October 05, 2026 | 330.81M |
| October 02, 2026 | 316.10M |
| October 01, 2026 | 320.65M |
| September 30, 2026 | 331.86M |
| September 29, 2026 | 337.12M |
| September 28, 2026 | 342.37M |
| September 25, 2026 | 330.29M |
| September 24, 2026 | 330.81M |
| September 23, 2026 | 326.96M |
| September 22, 2026 | 344.48M |
| September 21, 2026 | 340.97M |
| September 18, 2026 | 330.81M |
| September 17, 2026 | 336.42M |
| September 16, 2026 | 328.36M |
| September 15, 2026 | 331.51M |
| September 14, 2026 | 334.32M |
| September 11, 2026 | 342.72M |
| September 10, 2026 | 354.64M |
| September 09, 2026 | 366.90M |
| September 08, 2026 | 394.92M |
| September 04, 2026 | 392.82M |
| Date | Value |
|---|---|
| September 03, 2026 | 398.43M |
| September 02, 2026 | 390.02M |
| September 01, 2026 | 380.21M |
| August 31, 2026 | 391.42M |
| August 28, 2026 | 388.62M |
| August 27, 2026 | 371.10M |
| August 26, 2026 | 385.11M |
| August 25, 2026 | 369.00M |
| August 24, 2026 | 358.14M |
| August 21, 2026 | 354.28M |
| August 20, 2026 | 356.39M |
| August 19, 2026 | 374.60M |
| August 18, 2026 | 374.60M |
| August 17, 2026 | 373.20M |
| August 14, 2026 | 369.35M |
| August 13, 2026 | 381.26M |
| August 12, 2026 | 373.20M |
| August 11, 2026 | 406.49M |
| August 10, 2026 | 342.02M |
| August 07, 2026 | 364.27M |
| August 06, 2026 | 338.52M |
| August 05, 2026 | 327.31M |
| August 04, 2026 | 312.94M |
| August 03, 2026 | 294.73M |
| July 31, 2026 | 294.03M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| ACADIA Pharmaceuticals, Inc. | 2.522B |
| Alnylam Pharmaceuticals, Inc. | 30.80B |
| Anika Therapeutics, Inc. | 248.88M |
| Savara, Inc. | 867.94M |
| Vericel Corp. | 1.984B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.973M |
| Revenue (Quarterly) | 17.87M |
| Total Expenses (Quarterly) | 15.90M |
| EPS Diluted (Quarterly) | 0.0542 |
| Gross Profit Margin (Quarterly) | 95.97% |
| Profit Margin (Quarterly) | 11.04% |
| Earnings Yield | -1.20% |
| Normalized Earnings Yield | -0.7722 |